Despite encouraging earlier results, themuch-awaited follow-up phase III DIAS-2trial on ischemic stroke patients treated withdesmoteplase afterthe onset of symptomsdid not showany improvement inclinical response at90 days.
Despite encouraging earlier results, the much-awaited follow-up phase III DIAS-2 trial on ischemic stroke patients treated with desmoteplase after the onset of symptoms did not show any improvement in clinical response at 90 days.
In previous investigational trials, the new drug, which is derived from vampire bat saliva, was shown to have a highly specific action and to be safe and effective over a longer treatment window than tissue plasminogen activator (tPA). Dr. Werner Hacke and colleagues at the University of Heidelberg in Germany assessed patients with acute stroke who were randomized within three hours of symptom onset to receive desmoteplase or placebo. There were no statistically significant differences in response rates between low/high dose of desmoteplase or placebo (47%/36% versus 46%).
Findings appeared in the February issue of The Lancet Neurology.
over 17 years ago
International experts, cutting-edgetechnology impress RSNA newbieover 17 years ago
Radiology gets sent off to the washhouseover 17 years ago
Clinicians identify tacticsthat minimize risk of NSFover 17 years ago
Edgy NSF article may have gone too farover 17 years ago
Game changes with new portable and wireless digital radiographyover 17 years ago
Study confirms: Digitalmammo lengthens read timeover 17 years ago
Vertebroplasty data hint atnegative effect on survivalover 17 years ago
Incidental finding on MRIpoints to multiple sclerosisover 17 years ago
3D neuro imaging techniquerealizes Orwellian visionover 17 years ago
Imaging utilization increaseswhere radiologists wane
